甲卡西酮使用人群中焦虑及抑郁症状特征及危险因素分析

目的 了解甲卡西酮滥用人群的流行病学特征及该人群中焦虑/抑郁症状的特征。方法 对来自山西省某强制隔离戒毒所中主要滥用物质为甲卡西酮的人群进行横断面调查，并对该人群中焦虑及抑郁症状患病率及其影响因素进行分析。本研究分别采用汉密尔顿焦虑量表(HAMA)和BECK抑郁自评量表(BDI)评估调查对象的焦虑及抑郁症状。结果 本次研究共纳入767名研究对象，以已婚、低学历男性为主；12.6%的调查对象有多药滥用经历，且有48.4%的调查对象有甲卡西酮依赖；分别有15.3%和49.2%的甲卡西酮滥用者存在焦虑及抑郁症状。多因素logistic回归分析显示曾使用过2种及以上的合成毒品(aOR=2.13, 95%CI:1.26-3.61)、甲卡西酮依赖(1.77, 1.13～2.78)及抑郁症状(1.67, 1.10-2.54)是焦虑症状的危险因素，而参加过戒毒治疗(0.42, 0.27-0.64)是焦虑症状的保护因素；甲卡西酮的累计使用时间(>24个月)(1.41, 1.01-1.96)及焦虑症状(1.71, 1.14-2.55)是抑郁症状的危险因素。结论 甲卡西酮滥用后可导致焦虑及抑郁等精神症...     

我国苯丙胺类兴奋剂和K粉滥用人群用药后症状及戒断症状分析

目的:了解目前我国苯丙胺类兴奋剂(ATS)和K粉(主要成分为氯胺酮)滥用的基本情况及滥用后出现的症状、体征/行为和戒断症状的特点。方法:采用自拟调查问卷从2010年3月-2010年12月对北京、上海、云南、广东、湖南和湖北等地的强制隔离戒毒所或社区内的以滥用甲基苯丙胺(MA)、"摇头丸"(MDMA)、K粉或者"麻谷丸"为主的合成毒品滥用者进行回顾性调查,并统计分析人口学特征、合成毒品滥用情况、成瘾性、用药后的症状、体征/行为和戒断症状。结果:共调查1459名滥用者,男性占65.17%,平均年龄为(32.87±8.78)岁。将调查对象按主要滥用毒品种类分为三组:ATS(滥用主要毒品包括MA或MDMA或"麻谷丸")的有1191人(83.93%),K粉的有141人(9.94%),混用ATS+K粉的有87人(6.13%)。通过因子分析将用药后出现的症状、体征/行为归为6组症状群。有98.21%(1318/1342)的合成毒品滥用者出现了一定的用药后症状、体征/行为;兴奋症状在三组滥用人群中均最为严重,其中ATS和ATS+K粉前三位症状为失眠、兴奋和欣快,K粉为欣快、兴奋和失眠;第二位症状群在ATS和K粉中均为躯体症状,而ATS+K粉则为精神病性症状;且ATS+K粉的兴奋症状、精神病性症状,躯体症状和行为紊乱比ATS和K粉者严重。有90.88%(1215/1337)合成毒品滥用者停药后出现了一定的戒断症状,常出现的是用药渴求、困倦、疲乏无力、嗜睡、注意力不集中等。用药渴求在K粉和ATS+K粉中最为严重(排序第1位),在ATS中排名第4位,ATS中最为严重的戒断症状是困倦。结论:目前我国ATS和K粉的滥用状况具有不同的特点,并且用药后的症状和戒断症状在滥用ATS、K粉及混用两者的人群中存在差异,应根据各自特点制定相关的预防措施和治疗手段。     

甲基苯丙胺使用人群中焦虑症状特征及危险因素分析

目的:了解甲基苯丙胺(MA,俗称"冰毒")滥用人群的流行病学特征及该人群中焦虑症状的危险因素。方法:对来自北京市和深圳市的强制隔离戒毒机构中主要滥用物质为MA的共2644名人员进行问卷调查,并对该人群中焦虑症状患病率及其危险因素进行分析。本研究使用汉密尔顿焦虑量表(HAMA)评定研究对象的焦虑症状。结果:MA使用人群多是年龄较大、汉族、低学历男性; 289(10. 97%)名调查对象有多药滥用经历,其中有28. 69%的人曾经使用过海洛因,且有超过一半(56. 55%)的调查对象有MA依赖;有将近三分之一(29. 39%)的MA滥用者患有焦虑症状。多因素logistic回归分析结果显示每天使用MA(比值比(OR)=1. 80,95%confidence interval [95%CI]:1. 34-2. 42)、每次≥0. 2 g的使用剂量(1. 50,1. 18-1. 92)、使用MA的同时还是用其他毒品(2. 33,1. 37-3. 96)及抑郁症状(2. 13,1. 67-2. 70)和精神病性症状(9. 53,6. 99-13. 00)是焦虑症状的危险因素,而高中及以上的受教育水平(0. 64,0. 46-0. 89)、无业(0. 52,0. 40-0. 66)及参加过戒毒治疗(0. 46,0. 33-0. 65)是焦虑症状的保护因素。结论:焦虑症状是MA滥用人群中常见的精神症状,有近三分之一的MA使用者停止使用MA后会出现焦虑症状,我们可以通过积极治疗精神疾病共病、减少MA使用、进行戒毒治疗等措施来改善MA使用者的焦虑症状。     

海洛因依赖者出现精神症状的临床分析及护理

目的:探讨海洛因依赖者出现精神症状的临床特点并制订相应的护理措施。方法:选用《简明精神病量表》(BPRS)筛选出海洛因依赖者120例,按焦虑抑郁、缺乏活力、激活性、思维障碍和敌对猜疑等5个因子及其等级进行临床分析。结果:120例患者BPRS分为42·56±s8·31。各项因子分中,焦虑抑郁因子占首位,其后依次为思维障碍因子,缺乏活力因子、敌对猜疑因子以及激活性因子。结论:海洛因依赖者普遍存在焦虑抑郁情绪;多数存在感知和思维方面的精神症状。根据海洛因依赖者精神症状的特点有必要拟定合理护理措施,以解除患者的精神和躯体依赖,使其早日康复回归社会。     

苯丙胺和氯胺酮滥用者在精神症状致病作用的交互影响

目的:通过比较在苯丙胺类中枢兴奋剂和氯胺酮混合滥用者与相应单一药物滥用者之间所表现的精神症状的差异,推测两者在诱导精神症状方面的相互作用。方法:对2010年1月至2011年12月华中科技大学同济医学院附属精神卫生中心成瘾病房收治的苯丙胺类中枢兴奋剂,氯胺酮,及其混合滥用所致的精神障碍的患者的病例资料进行回顾性分析,分组别对患者入院时BPRS评定数据进行统计学分析。结果:(1)以氯胺酮为主的混合滥用组在焦虑抑郁因子分和活力缺乏因子分显著高于苯丙胺类中枢兴奋剂为主的混合滥用组(P<0.001),而在激活性因子分,思维障碍因子分,和敌意猜疑因子分显著低于苯丙胺类中枢兴奋剂为主的混合滥用组(P<0.001)。(2)以苯丙胺类中枢兴奋剂为主的混合滥用组在焦虑抑郁因子,活力缺乏因子分显著高于苯丙胺类兴奋剂单一滥用组;(3)以氯胺酮为主的混合滥用组BPRS总分,思维障碍因子,激活性因子,敌对猜疑因子分均显著高于氯胺酮单一滥用组。结论:氯胺酮可能加重苯丙胺类兴奋剂滥用者抑郁,失活性症状;苯丙胺类兴奋剂可能加重氯胺酮滥用者思维障碍,激活性和猜疑敌意,但可以减弱失活性症状,这提示苯丙胺类兴奋剂和氯胺酮所导致的精神症状可能存在不完全相同的精神病理学的机制。     

苯丙胺类兴奋剂、氯胺酮及其混合滥用所致精神障碍的临床精神症状的比较分析简

目的獉獉：比较分析苯丙胺类中枢兴奋剂、氯胺酮及其混合滥用所致精神障碍的住院患者临床精神症状的差异。方法獉獉：对2010年1月-2011年12月华中科技大学同济医学院附属精神卫生中心成瘾病房收治的苯丙胺类兴奋剂、氯胺酮、及其混合滥用所致的精神障碍375例患者的病例资料进行回顾性分析,分组别对患者入院时简明精神病评定量表评定数据进行统计学分析。结果獉獉：（1）苯丙胺类兴奋剂滥用组和苯丙胺类兴奋剂＋氯胺酮混合滥用组在简明精神病评定量表总分差异没有统计学意义（P〉0.05）,但他们都显著高于氯胺酮滥用组（P〈0.001）。3组5个因子分的两两比较差异均有显著意义（P〈0.01）。（2）苯丙胺类兴奋剂滥用组的思维障碍因子分、激活性因子分和敌对性因子分显著高于氯胺酮滥用组,而焦虑抑郁因子分、活力缺乏因子分显著低于氯胺酮滥用组,苯丙胺类兴奋剂＋氯胺酮混合滥用组则介于两者之间。（3）苯丙胺类兴奋剂滥用组和氯胺酮滥用组尿检阳性的患者简明精神病评定量表因子分和总分均显著高于尿检阴性的患者（P〈0.01）。结论獉獉：苯丙胺类兴奋剂、氯胺酮以及两种混合滥用所致精神障碍的精神症状存在明显差异,需要根据他们的临床特征制定相适宜的治疗措施。     

海洛因依赖者脱毒后不同时间对其心理症状的影响

目的:研究海洛因依赖者脱毒后不同时间对其心理症状的影响。方法:用SCL-90症状量表对住所不同时段的吸毒者进行评定,计算SCL-90症状10项因子在各戒毒月数分类组的均值和标准差,用单因素方差分析方法,对SCL-90症状10项因子在戒毒月数分类组间进行多重比较。结果:躯体化、抑郁、焦虑、精神病性、睡眠饮食障碍在戒毒1月组与戒毒2月组、3～6月组、半年以上组和精神病性、睡眠饮食障碍在戒毒2月组与戒毒半年以上组因子均分比较,有显著差异(P<0.05);人际关系敏感、恐怖、偏执在戒毒1月组与戒毒3～6月组、半年以上组因子均分比较,有显著差异(P<0.05);强迫症状在戒毒1月组与戒毒3～6月组、半年以上组和戒毒2月组与戒毒半年以上组因子均分比较,有显著差异(P<0.05);敌对在戒毒1月组与戒毒3～6月组因子均分比较,有显著差异(P<0.05)。结论:⑴缓解躯体化、抑郁、焦虑、精神病性、睡眠饮食障碍需要戒毒2个月;⑵缓解强迫症状、人际关系敏感、恐怖、偏执需要戒毒3个月以上;⑶缓解敌对需要3～6个月,在康复中,某些心理应激因素会使戒毒者产生敌对等情绪。     

计算机认知矫正对精神分裂症患者精神病症状和焦虑抑郁情绪及睡眠质量的影响研究

目的：研究计算机认知矫正(CCRT)对精神分裂症(SZ)患者精神病症状、焦虑、抑郁情绪及睡眠质量的影响。方法：选择2020年10月—2021年9月赣州市第三人民医院治疗的50例SZ患者作为研究对象,按随机数字表法分为对照组和观察组,每组25例。对照组采用利培酮治疗,观察组在对照组基础上采用CCRT治疗,共4周。比较两组精神病症状、睡眠质量、焦虑、抑郁情绪及不良事件发生情况。结果：治疗后观察组阳性和阴性症状评定量表(PANSS)评分、失眠严重指数(ISI)评分、汉密尔顿焦虑量表(HAMA)评分、汉密尔顿抑郁量表(HAMD)评分及不良事件发生率均低于对照组,差异有统计学意义(P<0.05)。结论：在SZ患者中采用CCRT治疗是安全可行的,有利于改善精神病症状及睡眠质量,减轻患者焦虑、抑郁情绪,降低不良事件的发生率。     

肺癌患者心理健康状况调查及其影响因素分析

目的调查肺癌患者心理健康状况并对其影响因素进行分析。方法应用症状自评量表(SCL-90)、抑郁自评量表(SDS)、焦虑自评量表(SAS)对住济南军区总医院的136例肺癌患者进行问卷调查。结果 (1)抑郁发生率为55.88%,轻度抑郁为44.12%,中度抑郁为11.76%;焦虑发生率为32.35%,其中轻度焦虑为20.59%,中度焦虑为11.76%。肺癌患者人际关系敏感、抑郁、焦虑、敌对、偏执和精神病性与全国常模相比差异有统计学意义,抑郁、焦虑和敌对显著高于全国常模,人际关系敏感、偏执和精神病性低于全国常模。(2)在相关分析中,心理状态与SCL-90总评分、躯体化、强迫、人际关系敏感、抑郁、焦虑、敌对、恐怖、偏执和精神病性相关。(3)多元逐步回归分析显示,年龄、医保类别、婚姻状况、生活环境、伴其他疾病、知晓病情、病程、职业、吸烟史、手术史、SCL-90总评分、躯体化、强迫、抑郁、焦虑、敌对、恐怖、偏执、精神病性等因素影响抑郁状态;性别、年龄、医保类别、婚姻状况、生活环境、知晓病情、病程、吸烟史、手术史、躯体化、人际关系敏感、焦虑、敌对、恐怖、精神病性等因素影响焦虑状态。结论肺癌患者抑郁、焦虑的发生率较高;性别、年龄、医保类别、婚姻状况、生活习惯、吸烟史、手术史、知晓病情和人际关系敏感、敌对、恐怖和精神病性等不健康心理等因素可影响肺癌患者的抑郁和焦虑等心理状态。     

曲唑酮与丁丙诺啡治疗海洛因依赖者稽延性戒断症状的对照研究

目的：观察曲唑酮对海洛因依赖者稽延性戒断症状的治疗效果及不良反应。方法：120例海洛因依赖者伴稽延性戒断症状患者随机分为曲唑酮组（n=60例）和丁丙诺啡组（n=60例）,均治疗4周,采用稽延性戒断症状评定量表,汉密顿焦虑量表（HAMA）、汉密顿抑郁量表（HAMD）以及不良反应量表cress）分别于治疗前及治疗后第1周末、第2周末、第4周末评定疗效和不良反应。结果：曲唑酮和丁丙诺啡对海洛因稽延性戒断症状均有显著疗效。．曲唑酮对焦虑、抑郁症状有明显疗效,丁丙诺啡对焦虑、抑郁症状无明显疗效,两组间差异有显著性。曲唑酮组不良反应明显小于丁丙诺啡组。结论：曲唑酮能有效治疗海洛因依赖者稽延性戒断症状和焦虑、抑郁症状,值得临床推广应用。     

TOXIC AND CARCINOGENIC EFFECTS OF PARENTERAL AND PERCUTANEOUS ATP AND ITS IRON COMPLEX

ABSTRACT

The long term effects of percutaneous, subcutaneous and intraperitoneal administration of sodium–ATP (NaATP) and ferric iron–ATP (FeATP) were studied on an animal model. Both compounds induce a generalized lymphoadenitis which in the case of FeATP led to lymphomas. The analytical study of the involved target tissues showed intracellular composition changes that result from the impairment of the cell membrane permeability. The morbidity and mortality rate were higher with FeATP which seems to be the result of two different, in intensity and duration, interactions with the cell plasma membrane. The influence of the changes in cellular calcium homeostasis, and its relationship with carcinogenesis and immuno response are discussed.     

苦参碱及氧化苦参碱的药代动力学与药效动力学

以QTc延长率为效应指标,用药代动力学-药效动力学结合模型对苦参碱、氧化苦参碱iv后在免体内的处置和效应动力学作定量分析,两药的血浓时程均符合二房室模型,两药的效应与效应室浓度之间的关系均符合S形E_max模型。两药彼此的药动学和药效学性质均有明显差异,但它们各自的劳动学和药效学性质在所用剂量范围内均为非剂量依赖性。     

LIVER ALCOHOL AND ALDEHYDE DEHYDROGENASE: INHIBITION AND POTENTIATION BY HISTAMINE AGONISTS AND ANTAGONISTS

1. The in vitro effects of histamine, some other Hi- and H₂-receptor agonists and some antagonists were studied on the specific activities and kinetics of rat liver alcohol dehydrogenase (ADH), and cytoplasmic and mitochondrial liver aldehyde dehydrogenase (ALDH). 2. Histamine (H₁- and H₂-agonist) non-competitively inhibited ADH and ALDH, 2-(2-aminoethyl) pyridine (Hi-receptor agonist) non-competitively inhibited ADH. There were no changes of cytoplasmic and mitochondrial liver ALDH activities in the presence of 2-(2-aminoethyl) pyridine. 3. Betazole (H₂-receptor agonist) produced a competitive inhibition of mitochondrial ALDH but not of ADH or cytoplasmic ALDH. 4. Diphenhydramine (H₁-receptor antagonist) non-competitively inhibited ADH at a lower concentration. It stimulated mitochondrial ALDH activity without changes in cytoplasmic ALDH from control values. 5. Burimamide (H₂-receptor antagonist) produced a biphasic and dose-dependent stimulation and non-competitive inhibition of ADH and it non-competitively inhibited ALDH in both cytoplasmic and mitochondrial fractions. Metiamide (H₂-receptor antagonist) non-competitively inhibited all ADH and ALDH of both liver fraction studied. 6. It is concluded that liver ADH and ALDH activity can be altered by compounds which affect both Hi- and H₂-histamine receptors and that these compounds may cause an in vivo potentiation and/or reduction of the toxic effect of ethanol.     

珍珠母贝中糖胺聚糖的提取分离纯化

目的:对马氏珍珠母贝中提取、分离得到的糖胺聚糖(glycosam inog lycans,GAG)进行化学组分研究。方法:样品经还原、水解和乙酰化,采用气相色谱-质谱法定性测定。结果:测定出马氏珍珠母贝中经提取、分离得到的GAG中的3种主要成分,其骨架结构分别与(硫酸乙酰)肝素、(硫酸)软骨素和透明质酸相符。结论:马氏珍珠母贝中提取分离的糖胺聚糖中含有肝素、软骨素和透明质酸。     

TOXICOKINETICS AND EFFECTS OF FIBROUS AND NONFIBROUS PARTICLES

Chronic inhalation of fibrous and nonfibrous particles by rats at high concentrations results in lung tumor formation if the particles are poorly soluble in the lung. Even rather benign nonfibrous particles such as TiO 2 produce this result. One significant change during a chronic inhalation exposure of poorly soluble particles of low cytotoxicity (PSP) is an impairment of normal clearance mechanisms in the alveolar region of the lung in rats, resulting in a continued buildup to high lung burdens accompanied by chronic alveolar inflammation, fibrosis, and mutational events. Since these are obviously high-dose effects, questions about their extrapolation to humans exposed to much lower concentrations have been raised. Results of key studies reported for chronic inhalation of PSP in rats indicate that mechanisms of PSP-induced lung tumors at high doses do not operate at low dose levels. Furthermore, the existence of two thresholds can be postulated: One is a dosimetric threshold for the endpoint alveolar macrophage-mediated clearance, which is related to lung particle overload. The other is a mechanistic threshold for the endpoint mutation, which is determined by the level of antioxidant defenses to counter-balance reactive oxidant species released by activated inflammatory cells. A no-observed-adverse-effect level (NOAEL) could therefore be based on avoiding alteration of the toxicokinetic of the particles such that the lung burdens stay below the dosimetric threshold. The suggestion that PSP-associated organic compounds (e.g., diesel particulate matter) contribute to the lung tumor responses in rats observed in chronic inhalation studies is not supported by experimental data from in vivo studies. It can be concluded that high-dose rat lung tumors due to PSP should not be used for low-dose extrapolations, and no significant contribution to human lung cancer risk can be predicted from levels of PSP below lung overload. With respect to the pulmonary toxicokinetics of inhaled fibrous particles, the biopersistence of long fibers (>20 µm) which cannot be phagocytized by alveolar macrophages is a key parameter related to long-term carcinogenic effects. Long fibers with a very low biopersistence should not be considered as carcinogenic. Since the clearance kinetics of fibers can generally be described by a biphasic or multiphasic pattern - fast initial and slow final phase - it is essential that the slow phase of the retention kinetics of fibers longer than 20 µm is considered in a biopersistence assay. Based on the results of such assay, fibers can be classified into one of two categories: a biopersistent fiber that cannot be dissolved in the lung within an acceptable time period; or a biosoluble fiber when even long nonphagocytizable fibers will be disappearing rapidly from the lung. However, in addition to biopersistence, it should be mandatory to evaluate fiber toxicity in an appropriate assay relative to a fiber whose long-term effects are well known. Moreover, for organic fibers it is likely that different rules may have to be established for characterization of their toxic and carcinogenic potential.     

HPLC和~1HNMR分析确定cis－A－和cis－B－羟甲芬太尼的组成和构型

羟甲芬太尼（１）是一个强效的镇痛剂和高亲和、高选择性的阿片μ受体激动剂。通过ＨＰＬＣ和１ＨＮＭＲ分析，ｃｉｓ－Ａ－ｌ被确定为由等量的ｃｉｓ－（＋）－（３Ｒ，４Ｓ，２＇Ｓ）－ｌ和：ｃｉｓ－（—）－（３Ｓ，４Ｒ，２＇Ｒ）－１组成的外消旋体，ｃｉｓ－Ｂ－ｌ被确定为由等量的ｃｉｓ－（—）－（３Ｒ，４Ｓ，２＇Ｒ）－１和ｃｉｓ－（＋）－（３Ｓ，４Ｒ，２＇Ｓ）－１组成的外消旋体。     

SODIUM AND NORADRENALINE IN CEREBROSPINAL FLUID AND BLOOD IN SALT-SENSITIVE AND NON-SALT-SENSITIVE ESSENTIAL HYPERTENSION

1. The effects of dietary sodium on blood pressure and levels of sodium, other electrolytes and noradrenaline (NA) in the cerebrospinal fluid (CSF) and blood of 15 patients with essential hypertension were studied. The CSF and blood sampling was carried out after 7 days of a high salt intake (16-18 g/day) and after 7 days of a low salt intake (1-3 g/day). 2. Blood pressure and sodium concentrations in CSF and serum were significantly higher in the high salt period than the low salt period (CSF Na+ concentration: 147.7 +/- 0.4 mmol/L vs 145.3 +/- 0.5 mmol/L; P less than 0.001). Levels of CSF pressure and potassium or calcium concentrations were not different between the two periods. Plasma NA and plasma renin activity (PRA) were lower and CSF NA levels tended to be lower in the high salt period. 3. The levels and the changes in sodium and NA in CSF were not significantly different between the salt-sensitive (n = 8) and the non-salt-sensitive (n = 7) subjects, but the changes in plasma NA and PRA were smaller in the salt-sensitive subjects. 4. These results indicate that the sympathetic nervous system is less suppressed in salt-sensitive subjects during high salt intake. This may be due to altered neural responsiveness to sodium loading rather than being greater increases in sodium concentration in the central nervous system.     

PLASMA AND PITUITARY PROLACTIN AND BLOOD PRESSURE IN BROMOCRIPTINE-TREATED SPONTANEOUSLY HYPERTENSIVE AND WISTAR-KYOTO RATS

1. The effects on blood pressure (BP) and plasma and pituitary prolactin (PRL) of a 13 day intraperitoneal infusion of bromocriptine delivered by osmotic minipump were investigated in spontaneously hypertensive rats (SHR) and their normotensive controls, the Wistar-Kyoto rats (WKY). 2. In the SHR, a fall in BP which was steepest over the initial few days and sustained up to day 12 was observed in the bromocriptine-treated group compared with the lack of a change in BP observed in the vehicle-treated group. The plasma PRL level taken on day 13 was found to be significantly lower in the bromocriptine-treated group than in the vehicle-treated group. 3. In the WKY, bromocriptine had no significant effect on either BP or plasma PRL. 4. Pituitary PRL content was significantly lower in the SHR than in the WKY. The suppression by bromocriptine treatment was greater in the SHR than in the WKY. 5. These results provide further evidence for a central dopaminergic insufficiency in the SHR and raise the possibility that PRL may, either directly or indirectly by interacting with other factors in the SHR, influence BP.     

冰毒吸食者焦虑抑郁情绪和自我概念的测评及相关分析

目的:了解冰毒吸食者焦虑抑郁情绪和自我概念状况,探讨二者之间的关系,为临床心理干预提供依据。方法:采用抑郁自评量表(SDS),焦虑自评量表(SAS)和田纳西自我概念量表(TSCS)对36例强制戒毒的冰毒吸食者(研究组)和36例健康人群(对照组)进行调查,将结果进行统计学处理分析。结果:(1)研究组SDS,SAS评分明显高于对照组,差别具有统计学意义(P<0.01);(2)TSCS评分比较,研究组除自我批评因子分高于对照组外,其余各因子分均低于对照组,差异具有统计学意义(P<0.01);(3)TSCS与SAS和SDS之间具有高度相关性(r=0.411-0.462,P<0.01)。结论:冰毒吸食者焦虑抑郁情绪明显,表现为消极的自我概念;焦虑抑郁情绪影响自我概念。临床治疗中应关注戒毒者负性情绪和自我概念,采取有效措施帮助他们消除负性情绪,树立积极的自我概念,促进心理康复。